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tionally, increased tissue expression of PlGF by IHC was seen
in skin biopsies of aGVHD, while GI aGVHD tissue demon-
strated pathologically low PlGF expression. To our knowl-
edge, these results provide the ﬁrst evidence of altered
circulating and tissue expression of PlGF occurring in the HCT
setting. Studies are ongoing to determine the role of PlGF in
neovascularization and tissue repair in aGVHD, and on the
direct angiogenic and immune regulatory effect of PlGF in
HCT.433
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Umbilical cord blood (UCB) is an alternative option for he-
matopoietic stem cell transplantation and it has been suc-
cessfully used to treat children with malignant and non
malignant diseases. The slower rate of neutrophil engraft-
ment and delayed immune reconstitution impose a sub-
stantial risk for infections and mortality. Furthermore, the
use of anti-thymocyte globulin (ATG) has been linked to a
higher risk of viral infections. In order to assess the occur-
rence of viral infections we retrospectively analyzed the
outcomes of 156 children who underwent a UCB transplant
(UCBT) between January 1996 and October 2012 in a single
institution. Diagnostic methods varied over time: initially
antigenemia, immunoﬂuorescence and immunoenzymatic
tests were used and since 2005 Polymerase Chain Reaction
(PCR) was employed for vigilance and diagnosis of viral
reactivation. Fifty-one girls and 105 boys with a median age
of 60 months (range 2 e 168 months) were transplanted for
malignant (48 pts) and non-malignant diseases: BM failure
syndromes: 55 patients (pts), primary immunodeﬁciencies
(PID): 41 pts and inborn errors of metabolism (IEM): 12 pts.
HLA compatibility: 6/6 or 5/6: 98 pts and 4/6: 58 pts. Con-
ditioning Regimen was based on chemotherapy in 119 pts
and TBI based in 37 pts. The median number of Total
Nucleated Cell was 5.2 x 107/Kg (range: 1.4 - 36.4 x 107/Kg).
One hundred and forty-three pts were evaluable for
engraftment with a median time for neutrophil recovery of
26 days and for platelet recovery of 42 days. Viral infection
occurred in 99/156 pts. In the univariate analysis it was more
frequent in pts who received ATG: 87/122 (p 0.0001), in
those who developed acute GVHD: 65/80 (p 0.0001) or
chronic GVHD: 49/59 (p 0.0001) and in 4/6 HLA mismatched
UCBT (p 0.001). The most frequent virus detected in this
cohort was Cytomegalovirus (CMV): 74 pts, followed by
Epstein-Barr virus (EBV): 14 pts and adenovirus: 8pts. CMV
status pre-transplant correlated with higher incidence of
CMV infection post transplant. Moreover, viral infections
were associated with bacterial infection in 79/127 pts
(p 0.01). Death occurred in 81 pts and the main cause wasbacterial infection. In this analysis the presence of viral
infection per se was not associated with a high mortality.
Conclusion: We observed a high prevalence of viral in-
fections among UCB recipients and a positive association of
its occurrence with HLA-mismatch, development of acute or
chronic GVHD and the use of ATG. Viral infections were
usually associated with other infectious agents such bacteria
or fungi and this could be an important factor for morbidity
and mortality. Currently, close PCR surveillance allows early
detection of viremia and aggressive treatment.434
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Background: CMV recipient seropositivity (R+) is a predictor
for CMV viremia after SCT. Cytotoxic T-lymphocytes (CTL) are
critical for CMV immunity. Conventional allografts from CMV
seropositive donors (D+) confer some CMV immunity though
transfer of donor CTLs to the recipient. Thus for CMV R+, CMV
D+ are preferentially chosen over CMV D-. In contrast, ex-
vivo T-cell depleted (TCD) allografts are deﬁcient in CMV
CTLs. The effect of donor serostatus on CMV reactivation has
not been examined after TCD SCT. We studied the effect of
CMV donor serostatus on the incidence of CMV viremia in a
cohort of adult CMV R+, TCD SCT monitored by CMV PCR and
treated preemptively.
Methods: CMV R+ adults with hematologic malignancies
who received peripheral blood CD34+ selected allografts
after myeloablative conditioning regimens from March 1,
2010 through May 2013 were monitored prospectively by
CMV PCR at least weekly from day (d) +14 through +100 and
at least once every 2 weeks through d +180. Preemptive
therapy was initiated for CMV viremia, deﬁned as  1 posi-
tive PCR value. There was no CMV prophylaxis during the
study period. Follow up was through May 31, 2014. Time-
dependent Cox-proportional hazard model of univariate and
multivariate stepwise selection analyses were performed to
identify predictors of CMV viremia.
Results: Of 113 CMV R+ (median age 57.6 years, 22.5-73.0),
60 (53%) had acute leukemia, 23 (20%) myelodysplastic
syndrome, 18 (16%) multiple myeloma and 12 (11%) other.
Donors were 48 (42%) matched-related (MRD), 45 (40%)
matched unrelated (MUD), or 20 (18%)mismatched; 68 (60%)
CMV D+ or 45 (40%) D-. The cumulative incidence of CMV
viremia at 6 months was 79%. Time to onset of viremia was
median 26 days (13-83) after SCT, and time to resolution of
viremia a median 30.5 days from onset of viremia. The inci-
dence of CMV viremia was higher in R+/D+ compared to R+/
D- (90.5% versus 62.2%; P<0.0001). Median time to onset and
to resolution for R+/D+ vs R+/D- were not signiﬁcantly
different. In multivariable analysis, R+/D- pts were at lower
risk for CMV viremia compared to R+/D+ (HR: 0.57, 95% CI:
0.36-0.90; P¼0.017). In contrast, multiple myeloma (HR:
2.22, 95% CI: 1.24-3.98; P¼0.008) was associated with
increased risk compared with acute leukemia. Having a
mismatched donor was also associated with increased risk
